Clinical Trials Directory

Trials / Unknown

UnknownNCT05760508

Novel Markers of Disease Progression in Interstitial Lung Disease

Status
Unknown
Phase
Study type
Observational
Enrollment
120 (actual)
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Academic / Other
Sex
All
Age
40 Years – 90 Years
Healthy volunteers
Not accepted

Summary

Study design: A prospective cohort study with a longitudinal design, with several parameters measured serially at baseline and at pre-specified time points during three to five years of clinical observation. Primary objective: To validate quantitative analysis of lung sounds as a marker of disease progression in a cohort of patients with Interstitial Lung Disease (ILD) via correlation with the extent of fibrosis on HRCT, measured both via visual scoring and quantitative CT assessment, and other validated parameters of disease progression such as FVC, tolerance to exercise and patient-related outcomes (symptoms and quality of life). Secondary objectives: To determine the prognostic value of quantitative analysis of lung sounds and a series of novel putative biological markers, obtained from peripheral blood and bronchoalveolar lavage, toward poor outcomes (death, categorical decline of % predicted FVC \>10%, acute exacerbation or respiratory-related hospitalisations) as compared to more conventional clinical, physiology and radiologic measurements.

Conditions

Timeline

Start date
2018-07-23
Primary completion
2022-03-30
Completion
2024-01-01
First posted
2023-03-08
Last updated
2023-03-08

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05760508. Inclusion in this directory is not an endorsement.